For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives.

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and identifies a new combination treatment. Publishing in Nature Immunology, ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

BERLIN -- After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

A landmark study headed by researchers at Yale School of Medicine and at Fred Hutchinson Cancer Center has revealed that autoantibodies (AAbs)—immune proteins traditionally associated with autoimmune ...

After months of shrinking scans, the tumors suddenly came roaring back. Oncologists have seen this pattern for years in patients on immunotherapy and targeted drugs: a dramatic initial response, then ...